CLR discusses the role of CB2 (Cannabinoid Receptor Type 2) in skin health and how it is feasible to have a true ‘neurocosmetic’ effect when the possibility exists for a cosmetic active ingredient to act as an agonist to CB2 on the outermost skin cells, the keratinocytes. The German firm has developed a cherimoya-based active to achieve this
A deep dive into consumer physiology and psychology teaches us that increasing numbers of consumers feel that they have problems with their skin. Virtually nobody is fully satisfied with their skin, approximately 50% of all consumer perceive their skin to be sensitive and more and more people seem to suffer from skin diseases such as atopic dermatitis and psoriasis.
Although cosmetic products cannot and are not allowed to cure skin diseases, especially dermocosmetic products are recognized to offer effective support. It is not for nothing that the dermocosmetic segment of the skincare industry has shown strong and constant growth over the last decade
Consumers, seemingly, rather first go to the pharmacy to buy a dermocosmetic product than go directly to a dermatologist and what they find in the pharmacies looks to provide satisfactory results for them.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
